Plné znění - 2/2008 Sb. m. s.

Ministerstvo zahraničních xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 bylo generálním xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx úmluvy proti xxxxxxx xx xxxxxx¹⁾, xxxxxxxx schválení xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx látek x xxxxx dopingu.

Xxxxxxx X vstoupila x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx Xxxxxxx I x xxxxxxxx xxxxxxxx xxxxxx Xxxxxxx X Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx xx xxxxx xxx xxx 2007, xxxxxxxxx xxx č. 59/2007 Xx. m. x.

Xxxxxxxx znění Xxxxxxx X a xxxx xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ LÁTKY

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (19-norandrostendiol); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); desoxymethyltestosteron (17α-metyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; formebolon; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-dimetyl-5α-androstan-3-on-17β-ol); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; oxymetolon; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

b. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

androst-5-en-3α,17α-diol 19-noretiocholanolon

androst-5-en-3α,17β-diol

X xxxxxxxxx, xxx xxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx přirozeně, xxxx se mít xx xx, xx Xxxxxx xxxxxxxx tuto Xxxxxxxxx xxxxx a xxxx xxxxxx xxxxxxxxx Xxxxxxxxx laboratorní xxxxx, xxxx se xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx nebo xxxxxxxxxxx x/xxxx xxxx xx jakýkoli xxxx xxxxxxxxx poměr xx Xxxxxx Xxxxxxxxx významně xxxxxxxxx od xxxxxxx xxxxxx, xxxxx xx xxxxxxxx vyskytují x xxxx xxx, že xxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx. Xxxxxx se xxx za xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxx xxxxxxx, pokud Xxxxxxxxx xxxxxxx, že xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx jejích xxxxxxxxxx nebo xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx xxxxxxxxxxxxx nebo xxxxxxxxxxxx xxxxxx.

Xxxx xx mít xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxxxxxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx xx xxxxx xxxxxxxxx x při xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx metody (např. XXXX) prokázat, že xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. V xxxxxxx případě není xxxxx provádět xxxxx xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx neodchylují od xxxxxxx xxxxxx, které xx xxxxxxxx vyskytují x xxxx a xxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, ale xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx, xxxx xxxx. xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxxxxx, xxxx když xxxxxxxxx nahlásila poměr X/X xxxxx než xxxxx (4) ku xxxxx (1) x xxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ xxxxx, provede xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxx porovnáním xxxxxxxx xxxxxxxxxx testů xxxx xxxxxxxxxx následných xxxxx.

Xx-xx vyžadováno xxxxxx xxxxx xxxxxxx, xxx xxxxxxxx xxxx laboratoří xxxxxx xxxx neobvyklý x ne xxxx xxxxxxxxx. Xxxxx xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx nutné xxxxxxxx xxxxx šetření, x xxxx xx xxx xx to, xx Xxxxxx obsahuje Zakázanou xxxxx. Xxxxx xxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, xxxx xxxxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx tím, xx xxxx xxxxxxxxxx Antidopingovou xxxxxxxxxx x následujících 3 měsících xxxxxxx xxxxxxxx bez xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx xxxxxx xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx normální, xxxx xx pak xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx.

X xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx může být x moči xxxxxx xxxxxxx xxxxxxxx endogenního xxxxxx ve xxxxxx xxxxxx koncentracích (xx/xx). Xxxxx xxxxxxxxx takový xxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxx xxxxxxxxx další xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx laboratoř nahlásila Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, xxxx se xx xxxxxxxxx xx xxxxxxx a přesvědčivý xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx xxxxx. V xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

X případě, xx Xxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, bude xx xxx xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx látku.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

X2. XXXXXXX X XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Erytropoetin (XXX);

2. Xxxxxxx xxxxxx (xXX), insulinu xxxxxxx xxxxxxx faktory (xxxx. XXX-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX);

3. Xxxxxxxxxxxxx (xxxx. XX, xXX), zakázané xxx x xxxx;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

Pokud Xxxxxxxxx xxxxxx xxxxxxxx, xx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, bude xx xxx xx xx, xx Xxxxxx xxxxxxxx Zakázanou xxxxx (xxx xx uvedeno xxxx) x xxxxxxxxx, xxx koncentrace Xxxxxxxx xxxxx nebo xxxxxx xxxxxxxxxx xx indikátorů x/xxxx příslušné xxxxxx xx Vzorku Xxxxxxxxx xxxxxxx xxxxxxxx hodnoty xxxxxxxx zjištěné x xxxx tak, xx xxxxxxxxxxxx xxxxxxxx endogenní xxxxxxxx.

Xxxxx xxxxxxxxx xxxxxxxxx, po užití xxxxxxxxxx analytické metody, xx Xxxxxxxx látka xx xxxxxxxxxx původu, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

S3. XXXX-2 AGONISTÉ

Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxxx X- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx xxxxx xx při xxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

I xxxx byla udělena xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx, xxxx xxxxx xxxxxxxxxxx (volný xxxx xxxxxxxxxx) vyšší než 1000 xxxxxxxxx x 1 xxxxxxxxx xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx neprokáže, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx v xxxxxxxx.

S4. ANTAGONISTÉ X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx skupiny xxxx xxxxxxxx:

1. Inhibitory xxxxxxxx, zahrnující:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:

4. Xxxxx modifikující xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX

Maskovací xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, epitestosteron, xxxxxxxxxx, xxxxxxxxxx xxxx-xxxxxxxxx (xxxx. xxxxxxxxxx, dutasterid), xxxxxxxxxxxxxxx (xxxx. albumin, dextran, xxxxxxxxxxxxxxxxx) a další xxxxx s xxxxxxxxx xxxxxxxxxxxx účinky.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, kanrenon, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (např. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, chlorothiazid), xxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (kromě xxxxxxxxxxxx, xxxxx není xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx není platná, xxxxx moč Xxxxxxxxx xxxxxxxx xxxxxxxxx xx xxxxxxx x prahovou xxxx xxxxxxxxxxx xxxxxxxx xxxx Xxxxxxxx látky (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

M2. CHEMICKÁ X FYZIKÁLNÍ XXXXXXXXXX

X3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx buněk, genů, xxxxxxxx elementů, nebo xxxxxxxxxx xxxxxxx genů, xxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (xxxxxx obou xxxxxx xxxxxxxxxx xxxxxxxxx (X- a X-) xxxxxxx) xxxx xxxxxxxx, x xxxxxxxx derivátů xxxxxxxxx v případě xxxxxx xxxxxxxx xxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2008.

Xxxxxxxxxxx zahrnují:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, xxxxxxxxxxx, fenkamin, xxxxxxxxxxx, fenprometamin, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (X-), metylefedrin****, xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, oktopamin, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxx, propylhexedrin, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, tuaminoheptan x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx xxxxxx xxxx xxxxxxxxxx xx specifickou xxxxx pouze, pokud Xxxxxxxxx prokáže, xx xxxx xxxxxxxxx dostupnost x xxxxxxx léčebných xxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx antidopingových xxxxxxxx, xxxx xx u xxx menší pravděpodobnost, xx xxxx xxxxxxx xxxxxxxx jako xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx deriváty, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Kanabinoidy (xxxx. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Všechny xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx zakázané. Xxxxxx užití vyžaduje xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, do xxxxx xxxxxx, do xxxxx xxxxxx, xxxxxxxxxx, xx xxxx) x inhalační xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx výjimku s xxxxxxxx xxxx uvedených.

Xxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxx xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, xxxx, xxxxxx xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx xxxxxx xxxxxxxx x nevyžadují žádnou xxxxx xxxxxxxxxxxx xxxxxxx.

X1. XXXXXXX

Alkohol (etanol) xx xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx sportech. Xxxxxxx xx bude xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx krve. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx sport (FIA) (0.10 x/x)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Letecké xxxxxx a xxxxxxxxxxxx (XXX) (0.20 g/l)

∙ Lukostřelba (XXXX, XXX) (0.10 g/l)

∙ Moderní xxxxxxx (XXXX) jen pro xxxxxxxxxx se xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx sport (XXX) (0.10 x/x)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Kuželky (IPC) (0.10 g/l)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx sportech.

∙ Xxxxxxxxxxxx xxxxx (XXX)

∙ Billiard (XXXX)

∙ Boby (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "match xxxx" - xxx xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, IPC) (xxxxxxxx xxxx Xxxx soutěž)

∙ Lyžování (XXX) - skoky xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, x snowboard X-xxxxx x "big xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx xxxxxxxx

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx x obdobné xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx soutěž)

∙ Xxxxx motorismus (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, pindolol, xxxxxxxxxxx, sotalol, timolol, xxx ne x xxxxxxxx pouze na xx

"Xxxxxxxxxx xxxxx"* xxxx vyjmenovány xxxx:

∙ Xxxxxxx Beta-2 xxxxxxxx v xxxxxxxx, xxxxx salbutamolu (volného xxxx glukuronidu) xxx xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx x xxxxxxxxxxxx (zařazen xx xxxxxxx X 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, meklofenoxát, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx v xxxxxx X6, xxx která Xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxx xxxxxxx x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Xxxxxxxxxxxxxxxxxxxx;

∙ Xxxxxxx;

∙ Všechny Xxxx-xxxxxxxxx.

*"X Xxxxxxx xxxxx být xxxxxxxxxxx xxxxxxxxxx látky, které xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxxxx xxxxxxxx v xxxxxxx xxxxxxxxx xxxxxxxxxxx, xxxx x nichž je xxxxx xxxxxxxxxxxxxxx, že xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx činidla." Xxxxxxxx xxxxxxxxxxxxxxx pravidla xxxxxxxxxx takovéto xxxxx xxxx xxxxxxxx snížený xxxxxx za xxxxxxxxxxx, xx "...Xxxxxxxxx xxxx xxxxx prokázat, xx Xxxxxxx xxxxxxxxxx xxxxx xxxxxx zamýšleno ke xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. nabyl xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x xxxxxxxxx xx 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx předpisů x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu.